One of the most pre-eminent preventative cardiologists in the world, with over 85,000 citations for my research and over 280 publications in top-quality peer-reviewed journals, I am the Professor of Public Health, Honorary Consultant Cardiologist, Head of Commercial Trials and Deputy Director of the Imperial Clinical Trials Unit at Imperial College London.
Having completed a postdoctoral fellowship at Harvard Medical School and an MPhil in epidemiology from the University of Cambridge, I am the lead investigator for several major global medical trials of novel therapies for the prevention of cardiovascular disease. With papers published the New England Journal of Medicine, Lancet, JAMA, Circulation and the Journal of the American College of Cardiology, my research focuses on the prevention of coronary disease, in particular cholesterol, lipids, diabetes, biomarkers and risk prediction.
In addition to being a Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal Colleges of Physicians (London and Edinburgh), I am also a member of the British Cardiovascular Society and President-Elect of the European Atherosclerosis Society (EAS).
The pioneer of the EAS Familial Hypercholesterolaemia (FH) Studies collaboration - the first and only global registry of FH - I have also served on the EAS Consensus panel for European Guidelines for the past 10 years, with key original research contributions having influenced European and American guidelines on prevention and having changed warning labels for common therapies by the FDA and EMEA.
Primary and Secondary prevention of cardiovascular disease
Diabetes and cardiology
2004: University of Sheffield
2007: University of Cambridge
1991: University of Birmingham